Thank you for visiting our related projects page. This page will be updated with similar and complimentary projects throughout the duration of the MERLIN project.
REDDSTAR is an EU funded project which will develop and test stromal cell therapy to treat for diabetes mellitus. The objective is to control blood glucose while also addressing a range of diabetic complications. MERLIN partners Orbsen Therapeutics and Pintail also collaborate on REDDSTAR.
MERLIN partners Orbsen Therapeutics and Pintail Limited participate in the FP7-funded project VISICORT. The project will design and initiate an optimised clinical trial strategy of immunomodulatory stromal stem cell therapy in high-risk human corneal transplant recipients.
STELLAR is an FP7-funded project interested in developing an alternative to renal replacement therapy making use of newly discovered kidney mesenchymal stem cells.
DECIDE is a Marie Curie initial training network that is working to advance our understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). The aim is to deliver new agents for use in differentiation therapy, responding to the urgent need for devise milder treatments, especially for older and frailer AML patients. MERLIN partner institutions University of Birmingham and Orbsen Therapeutics are also partners on DECIDE.
NEPHSTROM is a Horizon 2020-funded research project that l will deliver and validate a transformative mesenchymal stem cell (MSC) treatment for diabetic kidney disease (DKD), MSC therapy as has already demonstrated the potential to target the five major aspects of DKD – hypertension, inflammation, fibrosis, oxidative stress, and proteinuria – with a single treatment. MERLIN partners Orbsen Therapeutics, NHS Blood and Transplant and Pintail also participate in NEPHSTROM.